Kornimate/medical-research-clean huggingface dataset:
comparison of ebx and mohs surgery for treatment of early-stage non-melanoma skin cancer a matched pair cohort study.

Conditions: Nonmelanoma Skin Cancer

Summary: this is a retrospective-prospective study design. patients who completed treatment approximately 3 years (range of 2-4 years) at time of irb approval of this study will be identified and any existing data in the patient's record will be collected in addition to conducting office visits for long-term follow-up.

this is a retrospective-prospective study design. patients who completed treatment approximately 3 years (range of 2-4 years) at time of irb approval of this study will be identified and any existing data in the patient's record will be collected in addition to conducting office visits for long-term follow-up. the study will include 2 parts: 1. retrospective chart review: collect data from patient records who completed treatment a minimum of 2 years prior to study onset and determine the feasibility of doing a matched pair cohort study comparison of ebx versus mohs surgery. the history, demographic and treatment data will be retrospectively collected from up to 320 subjects previously treated with ebx for the treatment of nmsc and up to 320 subjects previously treated with mohs surgery for the treatment of nmsc. 2. prospective follow-up: patients will return for long-term follow-up visits for the investigators to assess the lesion site, document absence of recurrence/ absence of recurrence, toxicities, and collect patient reported outcomes.

Eligibility criteria:
inclusion criteria: 1. previously completed treatment for non-melanoma skin cancer using xoft ebx electronic brachytherapy system or mohs surgery; 2. provides informed consent; 3. greater than 40 years of age; 4. pathological diagnosis confirmed to be squamous cell or basal cell carcinoma prior to treatment; 5. cancer staging included in this study: * stage 0: tis, n0, m0 * stage 1: t1, n0, m0 * stage 2: t2, n0, m0 and ≤ 4cm in diameter exclusion criteria: 1. target area is adjacent to a burn scar 2. any prior definitive surgical resection of the cancer, prior to radiation treatment 3. known perineural invasion 4. actinic keratosis 5. known spread to regional lymph nodes 6. known metastatic disease
effect of cpap treatment on the elderly with mild to moderate sleep apnea

Conditions: Unrecognized Condition

Summary: objective: to analyze the impact of cpap treatment on cognitive, clinical and quality of life domains in patients over 70 years of age with mild-to-moderate osa primary outcome: epworth scale and qsq domains secondary outcomes: neurocognitive variables and cpap adherence


Eligibility criteria:
inclusion criteria: * age equal or greater than 70 years of both sexes * patients with sleep study results with ahi ≥ 15 and \< 30 exclusion criteria: * alternative diagnoses of other non-respiratory sleep disorders that are also cause of pathological somnolence (eg, sdr restless legs, narcolepsy, etc.) * don't sign informed consent * acute or chronic respiratory insufficiency requiring home oxygen therapy * patients with obesity hypoventilation syndrome * diagnosis of neuro-psychiatric diseases with the exception of anxiety - depression or diagnosis of dementia. * diseases of any origin in the acute phase * heart failure or recent stroke (less than 3 months). * central sahs (more than 50% of the registry with central apneas or cheyne-stokes breathing) * pre-treatment with cpap * inability to perform the diagnostic study of sleep due to the patient's condition * hipersomniaincapacitante (epworth≥18) with no known or most likely cause related to sahs

Keywords: sleep apnea elderly cpap
obesity and health-related quality of life in patients receiving bariatric surgery in the uk

Conditions: Quality of Life; Obesity, Morbid; Bariatric Surgery Candidate

Summary: united kingdom national bariatric surgery registry (nbsr) records between 1st june 2017 and 23rd november 2022 were used to identify people undergoing primary bariatric (weight-loss) surgery. people undergoing primary bariatric (weight-loss) surgery with one baseline and at least one follow-up visit within one year from surgery were included. statistical models were used to estimate the relationship between quality of life as assessed by a questionnaire and body mass index at baseline and over time.

previous small studies investigating health-related quality of life (hrqol) following bariatric surgery have demonstrated heterogenous effects. estimated changes in hrqol are used to evaluate both clinical- and cost-effectiveness of interventions; which in turn informs commissioning decisions. understanding hrqol of patients undergoing bariatric surgery is therefore important for both clinical practice and policymaking. this study aimed to use national bariatric surgery registry (nbsr) records to investigate the relationship between weight and hrqol in people undergoing bariatric surgery in the uk. the nbsr is an anonymised, bespoke record of bariatric cases carried out within the national health service (nhs) in the uk and ireland. the analysis plan was prospectively published in march 2022, and it is available here: https://osf.io/6t9rg/.

Eligibility criteria:
inclusion criteria: * adults (18 years or older) * undergoing primary bariatric surgery * with both baseline (pre-operative) and at least one follow-up record. exclusion criteria: * people undergoing revision surgery * records that did not include complete eq-5d scoring (all 5 domains). * records with implausible values, defined as: bmi \ 100 kg/m2; height \ 2.5m; weight \ 400kg; age\>100 years. * records greater than 12 months from surgery date
pharmacokinetic study of doxorubicin in children with cancer

Conditions: Wilms Tumor; Neuroblastoma; Soft Tissue Sarcoma; Acute Lymphoblastic Leukemia

Summary: analyze pharmacokinetics of doxorubicin in children with cancer. furthermore investigate the predictive role of troponin and natriuretic peptides for anthracycline-induced cardiotoxicity .

* paediatric patients up to the age of 17 years will be included. number and time points of pk sampling will depend on age and tumour type. * pk samples will be collected from two doxorubicin administrations. analyzing samples from two doxorubicin administrations will allow distinguishing between interindividual, intraindividual and residual variability. * doxorubicin and its major metabolite doxorubicinol will be measured in plasma using hplc * in addition, the natriuretic peptide bnp and the precursors nt-pro anp and nt-probnp as well as troponin t will be measured in plasma up to 28 days after doxorubicin administration to evaluate their use as clinical markers for cardiotoxicity. * a data set of max 5 samples (3 +2 (in the 1st + 2nd doxorubicin sampling periods)) will be collected in the younger children (\< 3 years) and a data set of max. 8 samples ( 5 + 3) will be collected in the older children. samples will be taken at predefined time points/ time intervals. * an additional dna sample will be taken and analyzed for genetic polymorphisms. the influence of genotype on pharmacokinetics and metabolism will be investigated by appropriate statistical methods, including population pharmacokinetic analyses. genes to study would include mdr1 and slc22a16, both involved in the transport of doxorubicin and akr1a1 and cbr1, both involved in the reduction of doxorubicin to doxorubicinol. selected genotypes will be incorporated as covariates into the population pharmacokinetic models developed. the potential impact of genetic variation will be evaluated in the context of other sources of variability such as age, weight, gender etc

Eligibility criteria:
inclusion criteria: * patients ≤ 17 years of age * plan to receive at least two cycles of doxorubicin * must be enrolled in a national or european protocol for treatment of wilms tumours, neuroblastoma, soft tissue sarcoma, ewing sarcoma or acute lymphoblastic leukaemia and must be treated with doxorubicin according to that protocol or patients \< 3 years enrolled or listed in any national or european study protocol for any paediatric malignancy. treatment with doxorubicin has to be according to that protocol. * parents or legal representative(s) must provide written informed consent to participate in the trial according to national regulations. patients that are able to understand should provide assent to participate in the trial. * life expectancy of at least 3 month * karnofsky performance status of ≥ 70% * additional blood withdrawal is acceptable for the patient. the decision is left to the investigator exclusion criteria: * prior cardiac problems

Keywords: pharmacokinetic doxorubicin cancer troponin natriuretic peptide cardiotoxicity anthracyclines ewing all
proposal to evaluate the efficacy of the interx 5000 in the treatment of chronic neck and shoulder pain

Conditions: Neck Pain; Shoulder Pain; Cervical Pain

Summary: the purpose of the proposed study is to evaluate the efficacy of the interx 5000 in relieving chronic neck and shoulder pain. this study will focus on the efficacy of treating patients who have functional limitations in activity because of chronic/recurrent neck or shoulder pain. h1: interx therapy will have a moderate effect to reduce pain. h2: functional gains will be greater in patients receiving interx therapy compared to those who received placebo treatment. h3: chronic neck and shoulder pain is more prevalent in patients who exhibit radiographic evidence of degenerative spondylosis/arthrosis of the cervical spine.

electrical stimulation modalities of various types have been used as a therapeutic intervention for years in a wide variety of applications. individuals with neck and shoulder pain represent a significant segment of the pain population seeking relief. however, there is a paucity of data from quality studies published in mainstream peer-reviewed journals supporting the effectiveness of this intervention. no well-designed prospective, randomized, controlled trials investigating the efficacy or effectiveness of this intervention in patients with chronic neck and shoulder pain have been reported. the need for such work is becoming increasingly important considering the progressively greater demands for evidence-based medicine to justify reimbursement for care.

Eligibility criteria:
inclusion criteria: * chronic or recurrent neck or shoulder pain of at least 3 months duration with or without arm pain * willing to sign consent for study participation * able/willing to comply with treatment schedule exclusion criteria: * clinically significant herniated disc (defined as positive radicular arm pain aggravated by head position change or neural stretch signs from provocative arm movement, this will not exclude patients with any imaged herniation as this is a common finding in all populations) * spinal fracture * previous electrical stimulation treatment for this episode * recent cervical spinal or shoulder surgery or implanted instrumentation/prostheses. * patients with cardiac pacemaker or spinal cord stimulator, epilepsy, pregnancy, recent (3 months) chemotherapy/radiotherapy, phlebitis, cortisone use (30 days)

Keywords: neck pain shoulder pain cervical pain chronic recurrent
nitrous oxide for ptsd

Conditions: PTSD

Summary: post-traumatic stress disorder (ptsd) seriously disrupts the lives of many veterans. current first-line treatments, serotonin reuptake inhibitors or prolonged exposure therapy, take weeks to months to bring meaningful improvement, leaving veterans experiencing prolonged suffering. a promising new treatment approach for rapidly reducing ptsd symptoms is nitrous oxide, an inhalation anesthetic and putative glutamate modulator that diminishes depression symptoms within 1 day and has limited side effects. if shown to be similarly effective in ptsd, nitrous oxide may add dramatically to the treatment armamentarium by bringing rapid symptom decrease before longer-term therapies take hold. the proposed projects test the efficacy of nitrous oxide in relieving veteran's ptsd symptoms and, in parallel, explore how nitrous oxide may modify cognitive and pain outcomes.

the proposed projects will examine the efficacy of nitrous oxide in relieving veteran's ptsd symptoms and in parallel, explore whether nitrous oxide improves cognitive and pain outcomes. specifically, the investigators will first assess whether nitrous oxide treatment improves ptsd symptoms within 1 week. in parallel, the investigators will explore whether the treatment improves co-existing depression and pain. in addition, the investigators will explore nitrous oxide's effects on a ptsd-associated impairment that is often overlooked - disruption in cognitive control, a core neurobiological process critical for regulating thoughts and for successful daily functioning.

Eligibility criteria:
inclusion criteria: * veteran * primary diagnosis of ptsd * sufficient severity of ptsd symptoms * capacity to provide informed consent exclusion criteria: * psychiatric or medical conditions that make participation unsafe * pregnant or nursing females * concurrent use of any medications that might increase the risk of participation (e.g. drug interactions

Keywords: ptsd nitrous oxide
study of auy922 and cetuximab in patients with kras wild-type metastatic colorectal cancer

Conditions: Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum

Summary: the study will determine the maximum tolerated dose (mtd) of auy922 given in combination with cetuximab in previously treated patients with kras wild-type metastatic colorectal cancer.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed colorectal cancer * kras wild type metastatic colorectal cancer * progression of disease on at least 2 prior therapy to have included 5fu, or oxaliplatin or bevacizumab or irinotecan * prior treatment with cetuximab is allowed (full dose tolerated), provided that the patient never required a dose reduction due to toxicities * must have at least one measurable lesion * must be 18 years of age or older * ecog performance status 0-1 * life expectancy must be greater than 12 weeks * for women of childbearing potential, a negative pregnancy blood test must be obtained less than 3 days prior to the first auy922 infusion exclusion criteria: * colorectal cancer with a kras mutation or in which the kras genotype status is unknown * metastasis to the cns * prior treatment with any hsp90 inhibitor compounds * patients who received systemic anti-cancer treatment prior to the first dose of auy922 within the following time frames: * radiotherapy, conventional chemotherapy: within 2 weeks * palliative radiotherapy: within 2 weeks * nitrosoureas, monoclonal antibodies, such as trastuzumab and mitomycin: within 6 weeks * any continuous-dosing (i.e. daily dosing, every-other-day dosing, monday-wednesday-friday dosing, weekly etc.) of systemic anti-cancer treatment for which the recover period is not known, or investigational drugs (i.e. targeted agents) within a duration of ≤ 5 half lives of the agent and their active metabolites (if any) * treatment of therapeutic doses of coumadin-type anticoagulants. \[maximum daily dose of 2mg, for line patency permitted\] * known sensitivity to cetuximab * unresolved ≥ grade 1 diarrhea * malignant ascites that require invasive treatment * concurrent medications that are substrates, inhibitors or inducers of cyp3a4, cyp2c8, cyp2c9 and cyp2c19 and cannot be switched or discontinued or switched to an alternative drug prior to commencing auy922 dosing need special consideration on a case by case basis * major surgery ≤ 2 weeks prior to randomization or who have not recovered from such therapy * impaired cardiac function

Keywords: colorectal neoplasms intestinal neoplasms gastrointestinal neoplasms digestive system neoplasms neoplasms by site neoplasms digestive system diseases gastrointestinal diseases colonic diseases intestinal diseases rectal diseases cetuximab hsp90 heat-shock proteins egfr protein, human
telemonitoring and e-coaching in hypertension

Conditions: Hypertension

Summary: rationale: hypertension is the most significant risk factor for cardiovascular disease and can be mitigated by lifestyle and medical management. telemonitoring as a novel management approach to perform hypertension management at distance has been thriving but became indispensable during the covid-19 pandemic. however, evidence of an effective implementation for telemonitoring remains to be elucidated. hypothesis: telemonitoring with a smartphone application, which includes mixed automated services for a personal counselling program (pcp), on top of self-monitoring (sm) will lead to improvement of hypertension control rates, medication adherence and lifestyle behaviors and lower health care costs in patients with hypertension when compared to usual care. objective: to investigate the effects of pcp+sm on hypertension control rate and lifestyle behaviors as compared with usual care. study design: the study is a non-blinded randomized controlled clinical trial in adults with hypertension, in a multicenter hospital setting . we will randomize participants in a 1:1 fashion to the intervention group (pcp+sm), or to the control group (usual care). study population: 400 patients, patients, aged ≥18 years with hypertension (rr \>140/90) main study outcome: hypertension control rate (%\<140/90mmhg) after 6 months (as measured by the sprint protocol)


Eligibility criteria:
inclusion criteria: * age ≥18 years * hypertension (\>140/90) * have and use a smartphone or a partner/caregiver who is able to provide the necessary technical support * able to provide written informed consent prior to participation in the study exclusion criteria: * current user of a blood pressure monitor apporoved by the dutch heart foundation in combination with the luscii app * persistent atrial fibrillation as indicated in the electronic health record (ehr) * pregnant or planning to become pregnant during the study period * severe kidney disease, defined as estimated glomerular filtration rate \<30 per 1.73 m2 or currently on renal replacement therapy (i.e. hemodialysis or peritoneal dialysis) * unable to communicate (not language specific) * recent cardiovascular event (ischemic stroke, transient ischemic attack, myocardial infarction, coronary artery bypass grafting) in the past 3 months * diagnosis of dementia, psychosis as indicated in the electronic health record * life expectancy \<1 year, for instance in terminal cancer or nyha iii or iv heart failure * individuals requiring bp monitor cuff size larger than 42cm * patients with proven secondary cause of hypertension for which drug treatment is not first choice (e.g. excessive licorice use, proven renal artery stenosis etc)

Keywords: telemonitoring hypertension e-health coaching
determine the prevalence and severity of asthma in hiv (human immunodeficiency virus) infected patients

Conditions: Asthma; HIV

Summary: the purpose of this study is to determine the prevalence and severity of asthma in patients with hiv. to determine the immunological phenotype of hiv-infected patients with asthma.

prospectively clinically phenotype and the prevalence of asthma in hiv infected patients in the duke id clinic * hiv infected asthmatic subjects meeting clinical definitions for asthma compared to hiv uninfected asthma subjects identified at the daaac and hiv infected non-asthmatic subjects. * prospective immunological phenotyping - hiv-infected asthma subjects prospectively identified and clinically phenotyped compared to hiv-uninfected asthma subjects identified at the daaac and hiv infected non-asthma subjects. regarding the sampling method of probability sample: all samples for hiv infected asthmatic patients, hiv uninfected asthmatic patients and hiv infected non-asthmatics patients will be analyzed. retrospectively determine overall asthma prevalence and severity among hiv-infected patients. retrospective immunological phenotyping (circulating cytokines) of hiv-infected patients utilizing available specimens in the duke hiv specimen biorepository * hiv-infected asthmatic subjects meeting asthma definition compared to overall asthma prevalence in u.s. population * hiv-infected asthma subjects meeting asthma definitions compared to matched hiv-infected non-asthma subjects

Eligibility criteria:
inclusion criteria: * hiv infected asthmatic and non-asthmatic adults ≥18 years * hiv uninfected asthma adults ≥18 years * females of childbearing potential have to be using medically acceptable contraceptive method for the duration of the study. * willing and able to give informed consent and adhere to visit/protocol schedules. * negative pregnancy test in women of childbearing potential * for asthma patients: known or possible diagnosis of asthma for at least one year exclusion criteria: * antibiotic administration for upper respiratory infection within the prior 30 days * greater than 10 pack a year smoking history * no prior use of steroids (systemic) within the past 3 months * underlying illnesses that may result in altered lung function * students or employees who are under direct supervision of any project or core pi/director. * pregnant or nursing mothers. * poorly controlled concomitant conditions as determined by the investigator. * subjects who have had an elective procedure (for example, colonoscopy, cystoscopy, etc.) within less than 2 weeks of the procedure date cannot be enrolled in the hiv asthma study * subjects must delay enrollment by 2 weeks into the hiv asthma study if they have received a single dose of systemic steroids
anatomical relationship between carotid artery and hyoid bone in stenotic and non-stenotic carotids

Conditions: Stenoses, Carotid; Stroke

Summary: ischaemic stroke is attributable to thromboembolism caused by carotid atherosclerotic disease in 18-25% of patients. guidelines for prevention of stroke (especially carotid endarterectomy) in patients with carotid atherosclerotic plaque are based on the quantification of the degree of stenosis. the hyoid bone, in proximity to the carotid artery, has been implicated in the pathophysiology of carotid artery dissection, atherosclerotic carotid disease, and compressive syndromes. in atherosclerotic carotid disease, pressure on the carotid artery induced by these bone structures has been proposed to play a possible role in plaque formation and rupture, leading to stenosis, occlusion, or artery-to-artery embolism. in a recent ultrasound study, dynamic displacement of the carotid artery with interference of the hyoid bone during swallowing, named as "flip-flop" phenomenon (ffp) has been associated with carotid artery stenosis and stenosis-related stroke. another study based on cta assessment observed no association between hyoid-carotid distance and plaque thickness, stenosis, or progression of thickness/stenosis. in that study, in almost two-third of the patients cta was performed for stroke/transient ischemic attack work-up, including a vast majority of patients with absence of carotid stenosis (median degree of carotid stenosis was 7%), and plaque-related stroke was not assessed. the objective of this study is to determine the anatomic hyoid-carotid interaction (ie, hyoid-carotid distance, carotid position relative to the hyoid bone, and hyoid morphology) based on cta and its relation to the degree of carotid stenosis and stenosis-related stroke.


Eligibility criteria:
* patients followed at the university hospital of nîmes between november 2016 and march 2020 * age \> 18 years * patients who underwent carotid endarterectomy for symptomatic or asymptomatic stenosis

Keywords: computed tomography carotid atherosclerotic plaque density stroke